urea has been researched along with abt 102 in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (25.00) | 29.6817 |
| 2010's | 12 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bayburt, EK; Faltynek, CR; Gomtsyan, A; Hannick, SM; Honore, P; Jarvis, MF; Lee, CH; Marsh, KC; McDonald, HA; Schmidt, RG; Sullivan, JP; Surowy, CS; Wetter, JM | 1 |
| Bayburt, EK; Bianchi, BR; Chu, KL; El Kouhen, R; Faltynek, CR; Gomtsyan, A; Han, P; Honore, P; Jarvis, MF; Lee, CH; McDonald, HA; McGaraughty, S; Neelands, TR; Niforatos, W; Sullivan, JP; Surowy, CS; Vos, M | 1 |
| Banfor, PN; Bayburt, E; Chandran, P; Daanen, JF; Faltynek, CR; Fryer, RM; Gauvin, DM; Ghilardi, JR; Gomtsyan, A; Hernandez, G; Honore, P; Jarvis, MF; Joshi, SK; Kort, ME; Kym, PR; Lee, CH; Mantyh, PW; Marsh, K; Mikusa, JP; Neelands, T; Reilly, RM; Segreti, JA; Sevcik, MA; Sullivan, JP; Surowy, CS; Zhong, C | 1 |
| Hutchins, CW; Kort, ME; Kym, PR | 1 |
| Chu, KL; Duan, RW; Faltynek, C; McGaraughty, S; Nothaft, W; Rowbotham, MC; Svensson, P; Wang, Y | 1 |
| Awni, WM; Dutta, S; Nothaft, W; Othman, AA | 2 |
| Kort, ME; Kym, PR | 1 |
| Brandl, M; Frank, KJ; Fricker, G; Hölig, P; Mägerlein, M; Rosenberg, J; Rosenblatt, KM; Westedt, U | 4 |
| Best, AE; Duan, WR; Faltynek, CR; Locke, C; Nothaft, W; Othman, AA; Reeh, P; Schaffler, K | 1 |
| Burgess, DJ; Gokhale, R; Jog, R; Jugade, N; Kumar, S; Shen, J; Tan, DC | 1 |
| Burgess, DJ; Gokhale, R; Jog, R | 1 |
| Garami, A; Gilbraith, K; Ibrahim, M; Khanna, R; Miko, A; Pakai, E; Patwardhan, AM; Pinter, E; Porreca, F; Romanovsky, AA | 1 |
2 review(s) available for urea and abt 102
| Article | Year |
|---|---|
Pharmacokinetics of the TRPV1 antagonist ABT-102 in healthy human volunteers: population analysis of data from 3 phase 1 trials.
Topics: Administration, Oral; Adult; Clinical Trials, Phase I as Topic; Dose-Response Relationship, Drug; Double-Blind Method; Female; Half-Life; Humans; Indazoles; Male; Middle Aged; Models, Biological; Randomized Controlled Trials as Topic; Time Factors; Tissue Distribution; TRPV Cation Channels; Urea; Young Adult | 2012 |
TRPV1 antagonists: clinical setbacks and prospects for future development.
Topics: Analgesics, Non-Narcotic; Benzimidazoles; Benzothiazoles; Body Temperature Regulation; Humans; Indazoles; Pyridines; Pyrimidines; Pyrrolidines; TRPV Cation Channels; Urea | 2012 |
3 trial(s) available for urea and abt 102
| Article | Year |
|---|---|
Oral and cutaneous thermosensory profile of selective TRPV1 inhibition by ABT-102 in a randomized healthy volunteer trial.
Topics: Abdomen; Administration, Cutaneous; Administration, Oral; Adolescent; Adult; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Indazoles; Male; Middle Aged; Pain; Pain Threshold; Skin; Thermosensing; Time Factors; TRPV Cation Channels; Urea; Young Adult | 2011 |
An oral TRPV1 antagonist attenuates laser radiant-heat-evoked potentials and pain ratings from UV(B)-inflamed and normal skin.
Topics: Administration, Oral; Adult; Analgesics, Opioid; Cross-Over Studies; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Etoricoxib; Evoked Potentials; Hot Temperature; Humans; Indazoles; Lasers, Gas; Male; Pain; Pain Measurement; Pyridines; Severity of Illness Index; Skin; Sulfones; Tramadol; TRPV Cation Channels; Ultraviolet Rays; Urea | 2013 |
Effects of the TRPV1 antagonist ABT-102 on body temperature in healthy volunteers: pharmacokinetic/ pharmacodynamic analysis of three phase 1 trials.
Topics: Analgesics; Body Temperature; Circadian Rhythm; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Indazoles; Models, Biological; TRPV Cation Channels; Urea | 2013 |
11 other study(ies) available for urea and abt 102
| Article | Year |
|---|---|
Identification of (R)-1-(5-tert-butyl-2,3-dihydro-1H-inden-1-yl)-3-(1H-indazol-4-yl)urea (ABT-102) as a potent TRPV1 antagonist for pain management.
Topics: Administration, Oral; Analgesics; Animals; Biological Availability; Dogs; Haplorhini; Humans; In Vitro Techniques; Indazoles; Indenes; Microsomes, Liver; Pain; Rats; Stereoisomerism; Structure-Activity Relationship; TRPV Cation Channels; Urea | 2008 |
(R)-(5-tert-butyl-2,3-dihydro-1H-inden-1-yl)-3-(1H-indazol-4-yl)-urea (ABT-102) blocks polymodal activation of transient receptor potential vanilloid 1 receptors in vitro and heat-evoked firing of spinal dorsal horn neurons in vivo.
Topics: Action Potentials; Animals; Cell Line; Cells, Cultured; Dose-Response Relationship, Drug; Hot Temperature; Humans; Indazoles; Male; Posterior Horn Cells; Rats; Rats, Sprague-Dawley; TRPV Cation Channels; Urea | 2008 |
Repeated dosing of ABT-102, a potent and selective TRPV1 antagonist, enhances TRPV1-mediated analgesic activity in rodents, but attenuates antagonist-induced hyperthermia.
Topics: Analgesics; Animals; Body Temperature; Bone Neoplasms; Calcium; Disease Models, Animal; Drug Interactions; Fever; Indazoles; Inflammation; Male; Mice; Mice, Inbred C3H; Motor Activity; Osteoarthritis; Pain; Pain Measurement; Pain Threshold; Rats; Rats, Sprague-Dawley; TRPV Cation Channels; Urea | 2009 |
Analgesic potential of TRPV1 antagonists.
Topics: Analgesics; Animals; Benzothiazoles; Indazoles; Models, Molecular; Pyrimidines; Pyrrolidines; Structure-Activity Relationship; Temperature; TRPV Cation Channels; Urea | 2009 |
Impact of FaSSIF on the solubility and dissolution-/permeation rate of a poorly water-soluble compound.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Buffers; Caco-2 Cells; Dialysis; Humans; Indazoles; Intestinal Absorption; Intestinal Mucosa; Intestinal Secretions; Intestines; Micelles; Solubility; Solutions; Suspensions; Urea; Water | 2012 |
Amorphous solid dispersion enhances permeation of poorly soluble ABT-102: true supersaturation vs. apparent solubility enhancement.
Topics: Caco-2 Cells; Cell Survival; Dosage Forms; Humans; Indazoles; Permeability; Solubility; TRPV Cation Channels; Urea | 2012 |
The amorphous solid dispersion of the poorly soluble ABT-102 forms nano/microparticulate structures in aqueous medium: impact on solubility.
Topics: Colloids; Diffusion; Indazoles; Materials Testing; Microspheres; Nanoparticles; Particle Size; Particulate Matter; Solubility; Urea; Water | 2012 |
What is the mechanism behind increased permeation rate of a poorly soluble drug from aqueous dispersions of an amorphous solid dispersion?
Topics: Caco-2 Cells; Humans; Indazoles; Solubility; Urea; Water | 2014 |
Formulation design and evaluation of amorphous ABT-102 nanoparticles.
Topics: Chemistry, Pharmaceutical; Drug Design; Drug Evaluation, Preclinical; Indazoles; Nanoparticles; Particle Size; Urea; X-Ray Diffraction | 2016 |
Solid state drug-polymer miscibility studies using the model drug ABT-102.
Topics: Chemistry, Pharmaceutical; Drug Compounding; Drug Stability; Excipients; Indazoles; Polymers; Solubility; Solvents; Urea | 2016 |
Transient Receptor Potential Vanilloid 1 Antagonists Prevent Anesthesia-induced Hypothermia and Decrease Postincisional Opioid Dose Requirements in Rodents.
Topics: Analgesics, Opioid; Anesthesia; Animals; Benzothiazoles; Dose-Response Relationship, Drug; Female; Hypothermia; Indazoles; Male; Mice; Mice, Knockout; Pain Measurement; Pain, Postoperative; Pyrimidines; Rats; Rats, Sprague-Dawley; TRPV Cation Channels; Urea | 2017 |